Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2010 Mar 2.

Published in final edited form as: Int J Pharm. 2008 Jun 27;362(1-2):93–101. doi: 10.1016/j.ijpharm.2008.06.018

Table 3.

In vitro enzymatic stability of ACV prodrugs in Caco-2, rat plasma, intestine and liver homogenates.

	AACV		SACV		EACV		VACV		IACV
	Rate (k^* 10³)	Half life (hrs)	Rate (k^* 10³)	Half life (hrs)	Rate (k^* 10³)	Half life (hrs)	Rate (k^* 10³)	Half life (hrs)	Rate (k^* 10³)	Half life (hrs)
Caco2	10.1 ± 0.6	1.15 ± 0.07	2.1 ± 0.6	6.1 ± 2.2	2.82 ± 0.54	4.2 ± 0.7	11.9 ± 0.7	1.6 ± 0.15	1.8 ± 0.6	6.9 ± 1.9
Plasma	2.45 ± 0.35	4.8 ± 0.7	0.06 ± 0.02	195 ± 57	0.28 ± 0.04	42.4 ± 6.1	0.05 ± 0.02	226 ± 67	0.08 ± 0.006	139 ± 9.2
Intestine	105 ± 2.7	0.11 ± 0.002	5.7 ± 0.7	2.1 ± 0.2	1.42 ± 0.08	8.2 ± 0.5	18.5 ± 0.7	0.6 ± 0.02	8.8 ± 0.5	1.32 ± 0.07
Liver	--	^a	27 ± 3	0.44 ± 0.06	0.05 ± 0.002	223 ± 8.8	163 ± 9	0.07 ± 0.004	165 ± 0.9	0.07 ± 0.004

Values are mean ± S.D. (n = 3–6).

^*

min⁻¹.mg protein⁻¹

^a

No intact prodrug detected after 1 min.